2022 World Conference on Lung Cancer (ePosters)-EP04.02-005. First Comprehensive Lung Cancer Long-Term Survivorship Program

EP04.02-005. First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival

Pdf Summary

A comprehensive lung cancer long-term survivorship analysis was conducted to evaluate the late toxicities and overall survival of patients who have undergone multimodality treatment for lung cancer. The study included patients who have survived at least 36 months from the initial diagnosis. The patients participated in a comprehensive survivorship program that included restaging imaging, organ function tests, laboratory investigations, and quality of life and symptom control analysis. Late toxicities were categorized according to standardized criteria, and quality of life tests were conducted. The study found that patients who underwent aggressive multimodality treatment had relatively moderate late morbidity after three years of survival. Cardiac, lung, renal, and endocrine functions were not significantly impaired. Quality of life and symptom control scores were only moderately influenced by initial comorbidities. The study also found excellent overall survival in this selected group of patients. This is the first comprehensive analysis of long-term survivorship in lung cancer patients with extended surveillance data. The study highlights the importance of considering long-term toxicities and quality of life when evaluating the benefits of long-term survival in lung cancer patients.

Asset Subtitle

Martin Metzenmacher

Meta Tag

Speaker Martin Metzenmacher

Topic Global Health, Health Services Research, and Health Economics - Support to Patients and Staff

Keywords

lung cancer

long-term survivorship

late toxicities

overall survival

multimodality treatment

comprehensive survivorship program

restaging imaging

organ function tests

quality of life

symptom control analysis